CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
62.78
0.27%
Market Trading Hours* (UTC) Open now
Closes on Thursday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.16
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.026235 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026235%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004012 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004012%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 62.9
Open 62.8
1-Year Change -2.38%
Day's Range 61.57 - 62.8
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 11, 2024 62.90 0.33 0.53% 62.57 63.09 61.53
Sep 10, 2024 63.05 1.20 1.94% 61.85 63.26 61.36
Sep 9, 2024 62.19 0.92 1.50% 61.27 62.74 61.02
Sep 6, 2024 61.19 -1.45 -2.31% 62.64 63.50 60.90
Sep 5, 2024 62.90 -1.30 -2.02% 64.20 64.20 61.02
Sep 4, 2024 64.25 -1.74 -2.64% 65.99 66.67 63.93
Sep 3, 2024 66.24 1.26 1.94% 64.98 67.01 64.98
Aug 30, 2024 65.59 -0.22 -0.33% 65.81 66.18 64.71
Aug 29, 2024 65.86 0.59 0.90% 65.27 67.42 64.96
Aug 28, 2024 65.59 0.90 1.39% 64.69 65.84 64.69
Aug 27, 2024 65.58 0.71 1.09% 64.87 65.63 64.85
Aug 26, 2024 65.13 1.18 1.85% 63.95 65.34 63.68
Aug 23, 2024 64.07 0.67 1.06% 63.40 64.38 62.99
Aug 22, 2024 62.78 -1.28 -2.00% 64.06 64.12 62.59
Aug 21, 2024 64.08 -0.20 -0.31% 64.28 64.81 63.86
Aug 20, 2024 64.16 1.41 2.25% 62.75 64.71 62.75
Aug 19, 2024 63.18 1.13 1.82% 62.05 63.23 61.80
Aug 16, 2024 62.10 0.40 0.65% 61.70 62.41 61.15
Aug 15, 2024 61.61 0.29 0.47% 61.32 62.09 61.20
Aug 14, 2024 61.12 -0.08 -0.13% 61.20 61.90 60.89

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Incyte Company profile

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland and Japanese office in Tokyo. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream and other clinical development programs.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Incyte Corporation revenues increased 12% to $2.99B. Net income totaled $948.6M vs. loss of $295.7M. Revenues reflect JAKAFI revenues segment increase of 10% to $2.13B, OLUMIANT product royalty revenues segment increase of 99% to $220.9M. Net Income reflects Other Research and development decrease of 47% to $902.3M (expense), Change in fair value of acquisition-rela decrease of 37% to $14.7M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 400M auth.,124,585,982. issd. Insiders & stakeholders own 1.22%. IPO: 11/93, 2M shares @ $7.50by D. Blech and Co. PO 11/95, 1.7M shares @ $19 by Hambrecht & Quist. PO 9/97, 1.38M shs @ $67 by Hambrecht & Quist. 9/00, 11/97, 2-for-1 stock splits. 6/00, Name chgd. from Incyte Pharmaceuticals, Inc. PO:10.5M shares

Industry: Biopharmaceuticals

1801 Augustine Cut-Off
WILMINGTON
DELAWARE 19803
US

News

ECB Preview: cuts expected but the pace is uncertain

Markets expect the ECB to cut rates again in September, but how many more?

12:34, 11 September 2024

Market analysis: US CPI and PPI

Overview of upcoming US inflation data for August, with expectations for a year-over-year CPI drop to 2.6% and core CPI holding steady at 3.2%. Markets will also focus on U.S. PPI data, which is forecasted to show mild growth, reinforcing potential easing inflationary pressures.

07:56, 10 September 2024

Introducing Newsquawk: your new in-platform newsfeed

We are very excited to announce the launch of Newsquawk in the Capital.com platform and app. This new newsfeed is designed to help you get ahead with real-time headlines, personalised stories and in-depth reports – all available directly in the platform and app, where you need them.

14:09, 20 August 2024

Jackson Hole Preview: All eyes on Powell and Gold

The key focus this week will be on Jerome Powell and any insight he may give into the future of monetary policy.

15:24, 19 August 2024

All eyes on inflation: US and UK CPI take centre stage

Just over a month has gone by since the latest CPI data was released in the US and so much has happened since.

14:41, 13 August 2024

European stocks face resistance in their attempt to recover

European stocks struggle to recover as the tech sector faces continued downside pressure in Asia.

13:56, 9 August 2024

Global selloff continues on US economy fears

Thursday’s rise in jobless claims led to a market meltdown in the US stock market as investors became concerned that the Federal Reserve made the wrong decision by keeping rates unchanged on Wednesday.

14:40, 5 August 2024

People also watch

US100

19,336.70 Price
+0.360% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

XRP/USD

0.57 Price
+5.030% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

57,821.00 Price
+0.430% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,551.74 Price
+1.660% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 640,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading